Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients

doi:10.5306/wjco.v15.i7.848

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2041)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

1120

Figures (1-3)

250

Tables (1-3)

246

Sum=1663

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

253

Sum=305

Jul 24, 2024 (publication date) through Apr 3, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Jul 24, 2024; 15(7): 848-858
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.848

Table 2 Clinical outcomes of poly (ADP-ribose) polymerase inhibitor therapy in BRCA gene-positive breast cancer and homologous recombination deficiency-positive ovarian cancer patients

Cancer type	Patient	Stage	Response change to PARPi	Duration of PARPi	PARPi status at end of study
BRCA+ breast cancer, 5/15 (33.3%)	1	II	CR–DF	13 months+	On Rx
	2¹	II	PR–PR	40 days	Stopped
	3	III	CR–DF	17 months+	On Rx
	4	IV	PR–PR	5 months	Stopped
	5²	IV	PR	7 months	Stopped
HRD+ ovarian cancer, 4/6 (66.6%)	1	III	PR–DF	15 months+	On Rx
	2	IV	CR–DF	13 months+	On Rx
	3	IV	SD–PRF	20 months+	On Rx
	4	IV	CR–DF	25 months+	On Rx

¹Received three cycles of neoadjuvant chemotherapy and then lost to follow-up and received poly (ADP-ribose) polymerase inhibitor in the advanced stage.

²Received olaparib as first line. + indicates the status of still receiving poly (ADP-ribose) polymerase inhibitor at the time of data collection/study end.

CR: Complete remission, DF: Disease-free; HRD: Homologous recombination deficiency; PR: Partial response; PRF: Progression-free; SD: Stable disease.

Citation: Syed N, Chintakuntlawar AV, Vilasini D, Al Salami AM, Al Hasan R, Afrooz I, Uttam Chandani K, Chandani AU, Chehal A. Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients. World J Clin Oncol 2024; 15(7): 848-858
URL: https://www.wjgnet.com/2218-4333/full/v15/i7/848.htm
DOI: https://dx.doi.org/10.5306/wjco.v15.i7.848